Aminothiadiazole (NSC 4728) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group.

Abstract	Thirty-two evaluable patients with advanced epithelial ovarian cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Two patients had partial responses, 12 had stable disease, 16 had increasing disease, and two were inevaluable for response. Aminothiadiazole used in this dosage and schedule has minimal activity in ovarian carcinoma patients previously treated.
Authors	R F Asbury, J Wilson, J A Blessing, H J Buchsbaum, P J DiSaia
Journal	American journal of clinical oncology (Am J Clin Oncol) Vol. 9 Issue 4 Pg. 334-6 (Aug 1986) ISSN: 0277-3732 [Print] United States
PMID	3751971 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References	Antineoplastic Agents Thiadiazoles 2-amino-1,3,4-thiadiazole
Topics	Antineoplastic Agents (adverse effects, therapeutic use) Female Humans Ovarian Neoplasms (drug therapy) Thiadiazoles (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!